Table 2. Correlations of CCBL2 expression in BC tissues with clinicopathologic features.
| Clinical characteristics | Variable | No. of cases | CCBL2 expression | χ2 | P value | |
|---|---|---|---|---|---|---|
| High n (%) | Low n (%) | |||||
| Age | <60 | 589 | 404 (68.59) | 185 (31.41) | 0.7858 | 0.4108 |
| > = 60 | 513 | 339 (66.08) | 174 (33.92) | |||
| Gender | Female | 1090 | 736 (67.52) | 354 (32.48) | 0.4564 | 0.5437 |
| Male | 12 | 7 (58.33) | 5 (41.67) | |||
| Histological type | Infiltrating Ductal Carcinoma | 790 | 505 (63.92) | 285 (36.08) | 16.1545 | 0.001 |
| Infiltrating Lobular Carcinoma | 204 | 156 (76.47) | 48 (23.53) | |||
| Other | 107 | 82 (76.64) | 25 (23.36) | |||
| Molecular subtype | Basal | 142 | 82 (57.75) | 60 (42.25) | 49.4216 | 0.0005 |
| Her2 | 67 | 35 (52.24) | 32 (47.76) | |||
| LumA | 422 | 332 (78.67) | 90 (21.33) | |||
| LumB | 194 | 110 (56.70) | 84 (43.30) | |||
| Normal | 24 | 19 (79.17) | 5 (20.83) | |||
| ER | Indeterminate | 2 | 1 (50.00) | 1 (50.00) | 19.3441 | 0.0005 |
| Negative | 239 | 134 (56.07) | 105 (43.93) | |||
| Positive | 813 | 578 (71.09) | 235 (28.91) | |||
| PR | Indeterminate | 4 | 1 (25.00) | 3 (75.00) | 20.1547 | 0.0005 |
| Negative | 345 | 205 (59.42) | 140 (40.58) | |||
| Positive | 704 | 507 (72.02) | 197 (27.98) | |||
| HER2 | Equivocal | 180 | 129 (71.67) | 51 (28.33) | 11.7483 | 0.0085 |
| Indeterminate | 12 | 9 (75.00) | 3 (25.00) | |||
| Negative | 565 | 382 (67.61) | 183 (32.39) | |||
| Positive | 164 | 91 (55.49) | 73 (44.51) | |||
| T classification | T1 | 281 | 207 (73.67) | 74 (26.33) | 12.7439 | 0.013 b |
| T2 | 640 | 422 (65.94) | 218 (34.06) | |||
| T3 | 138 | 91 (65.94) | 47 (34.06) | |||
| T4 | 40 | 20 (50.00) | 20 (50.00) | |||
| TX | 3 | 3 (100) | 0 (0) | |||
| N classification | N0 | 516 | 350 (67.83) | 166 (32.17) | 3.4757 | 0.5072 |
| N1 | 367 | 255 (69.48) | 112 (30.52) | |||
| N2 | 120 | 73 (60.83) | 47 (39.17) | |||
| N3 | 79 | 51 (64.56) | 28 (35.44) | |||
| NX | 20 | 14 (70.00) | 6 (30.00) | |||
| M classification | M0 | 917 | 613 (66.85) | 304 (33.15) | 7.8213 | 0.021 |
| M1 | 22 | 10 (45.45) | 12 (54.55) | |||
| MX | 163 | 120 (73.62) | 43 (26.38) | |||
| Stage | I | 182 | 134 (73.63) | 48 (26.37) | 10.766 | 0.032 |
| II | 626 | 421 (67.25) | 205 (32.75) | |||
| III | 252 | 164 (65.08) | 88 (34.92) | |||
| IV | 20 | 8 (40.00) | 12 (60.00) | |||
| X | 14 | 10 (71.43) | 4 (28.57) | |||
| Lymph node status | No | 28 | 18 (64.29) | 10 (35.71) | 0.5126 | 0.5277 |
| Yes | 697 | 492 (70.59) | 205 (29.41) | |||
| Vital status | Deceased | 155 | 88 (56.77) | 67 (43.23) | 9.3118 | 0.0025 |
| Living | 947 | 655 (69.17) | 292 (30.83) | |||
| Sample type | Metastatic | 7 | 4 (57.14) | 3 (42.86) | 0.3367 | 0.6982 |
| Primary Tumor | 1097 | 740 (67.46) | 357 (32.54) | |||
| Menopause status | Inde | 34 | 24 (70.59) | 10 (29.41) | 3.1873 | 0.3683 |
| Peri | 40 | 29 (72.50) | 11 (27.50) | |||
| Post | 706 | 462 (65.44) | 244 (34.56) | |||
| Pre | 231 | 164 (71.00) | 67 (29.00) | |||
| Margin status | Close | 31 | 23 (74.19) | 8 (25.81) | 0.9229 | 0.6322 |
| Negative | 922 | 617 (66.92) | 305 (33.08) | |||
| Positive | 79 | 55 (69.62) | 24 (30.38) | |||
| Radiation therapy | NO | 445 | 290 (65.17) | 155 (34.83) | 1.9235 | 0.1859 |
| YES | 557 | 386 (69.30) | 171 (30.70) | |||
| Neoadjuvant treatment | NO | 1088 | 735 (67.56) | 353 (32.44) | 0.2119 | 0.7686 |
| YES | 13 | 8 (61.54) | 5 (38.46) | |||
| Targeted molecular therapy | NO | 46 | 32 (69.57) | 14 (30.43) | 0.0035 | 1 |
| YES | 533 | 373 (69.98) | 160 (30.02) | |||
| OS | Alive | 933 | 646 (69.24) | 287 (30.76) | 9.7778 | 0.0025 |
| Dead | 154 | 87 (56.49) | 67 (43.51) | |||
| RFS | Relapse-free | 816 | 566 (69.36) | 250 (30.64) | 4.8181 | 0.0375 |
| Relapse | 96 | 56 (58.33) | 40 (41.67) | |||
Abbreviations: Bold values of P < 0.05 indicate statistically significant correlations.
bFisher’s exact test.
Note: High n (%) and low n (%) added up to 100% in each subgroup. For example, high BBCL2 expression n (%) of “Age<60” = 404/589 = 68.59%; low CCBL2 expression n (%) of “Age<60” = 185/589 = 31.41%